The Medical Letter on Drugs and Therapeutics
The full issue is available to subscribers Subscriber Login   
Drugs for Type 2 Diabetes
Revised 5/17/18: Information on newly approved drugs, recently published clinical trials, and cardiovascular outcomes have been changed.
Revised 11/13/17: The price for Victoza was changed to $498.40 (from $249.20).
Revised 1/12/17: In the dulaglutide section, we mistakenly stated that Xultophy is a combination of albiglutide/insulin degludec; the correct combination of Xultophy is liraglutide/insulin degludec. We have also moved that sentence to the liraglutide paragraph.

The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal glycated hemoglobin (A1C) concentration without inducing hypoglycemia; the target is generally an A1C of <7%.1 Treating to this target has been shown to prevent microvascular complications (retinopathy, nephropathy, and neuro pathy), but whether it prevents macrovascular outcomes is unclear. An A1C target of <8% may be appropriate for older patients and those with underlying cardiovascular disease, a history of severe hypoglycemia, diabetes-related complications or comorbidities, or a long duration of disease.2,3

LIFESTYLE MODIFICATIONS — Diet, exercise, and weight loss can improve glycemic control and are recommended for all patients, but most patients with type 2 diabetes ultimately require drug therapy. In a 10-year randomized controlled trial in ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this issue:
Title: Issue 1512
Select version:
 Downloadable, electronic issue - $35
 Postal, hardcopy issue - $35